Fisher & Paykel Healthcare upgrades FY26 earnings outlook

Fisher & Paykel Healthcare has raised its FY26 revenue and profit guidance, with tariff updates on the horizon.

Laura Stewart

Author bio Laura Stewart is a Finance Editor at The Motley Fool, where she covers Australian and international equity markets. She joined the company in 2022, following a career transition from legal advisory work in Southeast Asia into the investment industry. Prior to her current editorial role, Laura spent three years as an Equity Analyst and Writer, producing investment research across the ASX, NYSE, and NASDAQ. Her coverage included small-cap growth companies, thematic investment ideas, and high-quality U.S.-listed businesses. Laura holds a Master of Applied Finance and brings additional expertise in accounting, taxation, and estate and wealth planning from her postgraduate studies. She also has a background in law and communications, which supports her analytical and reporting work in financial markets. Outside of work, she enjoys spending time in the Adelaide Hills with her flock of sheep. Education Laura holds a Bachelor of Laws, a Bachelor of Communication (Journalism), and a Bachelor of Commerce with majors in Accounting and Corporate Finance. In 2025, she completed a Master of Applied Finance at the University of Adelaide, receiving postgraduate awards in Accounting Concepts & Methods, Ethical Principles in Accounting & Finance, Real Estate Valuation & Investment, and Tax, Estate & Wealth Planning. Social media LinkedIn FYI – I am taking a break from social media at the moment, so this account isn’t active at the moment, but I will let you know when I rejoin. Favorite investment quote "Compound interest is the eighth wonder of the world. He who understands it, earns it... he who doesn't... pays it." — Albert Einstein

Published February 23, 8:04 am AEDT

The Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) share price is in focus after the company upgraded its FY26 revenue guidance to approximately $2.30 billion and lifted its net profit outlook.

Happy shareholders clap and smile as they listen to a company earnings report. — Image source: Getty Images

What did Fisher & Paykel Healthcare report?

Full-year FY26 operating revenue now expected to be around $2.30 billion (previously $2.17–$2.27 billion)
Net profit after tax (NPAT) raised to between $450 million and $470 million (previously $410 million–$460 million)
Guidance assumes NZ:US exchange rate of 60 cents as at 31 January 2026
Updated figures do not include any potential US tariff refunds

What else do investors need to know?

Fisher & Paykel Healthcare reported strong growth across its full range of Hospital products, contributing to the upgraded guidance. The company noted ongoing improvements in gross margin and operating margin, supported by efficiency gains and continuous improvement activities.

A major regulatory update came as the United States Supreme Court overturned tariffs imposed under the IEEPA, but Fisher & Paykel Healthcare continues to work through the refund process and potential implications. Management expects to provide a further update on any tariff impacts with the full-year results in May.

What did Fisher & Paykel Healthcare management say?

Managing Director and CEO Lewis Gradon said:

We have continued to see good growth across the full range of our Hospital products so far during our second half.

Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.

What's next for Fisher & Paykel Healthcare?

Looking ahead, management will provide more detail on tariff developments and possible refunds when announcing its full-year results. The company remains confident that cost increases from tariffs will be mitigated over time by ongoing efficiency efforts.

Fisher & Paykel Healthcare continues to focus on innovation, expanding its footprint in respiratory care, and driving sustainable, profitable growth. The company maintains that the long-term strategy and direction are unchanged.

Fisher & Paykel Healthcare share price snapshot

Over the past 12 months, Fisher & Paykel shares have risen 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

Automatic Renewal

By taking up this offer, you will also be enrolled in our auto-renewal program, which is our way of making your ongoing subscription easier by ensuring uninterrupted service. Don't worry, though – you're not locked in, and can cancel your auto-renewal at any time before each 'anniversary' date without question or penalty.